NCT04315987View on ClinicalTrials.gov

NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
COVID-19 Pneumonia
Interventions
BIOLOGICAL

NestaCell®

A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.

BIOLOGICAL

Placebo

Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.

Trial Locations (4)

Unknown

Hospital Vera Cruz, Campinas

Hospital de Barueri, São Paulo

IncCOR, São Paulo

UNIFESP, São Paulo

All Listed Sponsors
collaborator

Cellavita Pesquisa Científica Ltda

OTHER

collaborator

Hospital Vera Cruz

OTHER

lead

Azidus Brasil

INDUSTRY

NCT04315987 - NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter